Resolian Appoints Rob Stachlewitz as CEO, Honggang Bi as Chairman of the Board, and Pat Bennett as Chief Business Officer and President of Scientific Affairs
Resolian, a global bioanalytical and analytical sciences partner, announced key leadership changes. Rob Stachlewitz joins as CEO, while current CEO Pat Bennett transitions to Chief Business Officer and President of Scientific Affairs. Honggang Bi has been appointed Chairman of the Board. The company, backed by Ampersand Capital Partners and KKR, has expanded globally through acquisitions including Alliance Pharma, Drug Development Solutions, and Denali MedPharm, establishing operations across four continents. The reorganization aims to support growing client needs and enhance global operations.
Resolian, un partner globale nel campo delle scienze bioanalitiche e analitiche, ha annunciato importanti cambiamenti nella leadership. Rob Stachlewitz entra come CEO, mentre l'attuale CEO Pat Bennett passa a ricoprire il ruolo di Chief Business Officer e Presidente degli Affari Scientifici. Honggang Bi è stato nominato Presidente del Consiglio. L'azienda, sostenuta da Ampersand Capital Partners e KKR, si è espansa a livello globale grazie a acquisizioni come Alliance Pharma, Drug Development Solutions e Denali MedPharm, stabilendo operazioni su quattro continenti. La riorganizzazione mira a soddisfare le crescenti esigenze dei clienti e a migliorare le operazioni globali.
Resolian, un socio global en ciencias bioanalíticas y analíticas, anunció cambios clave en el liderazgo. Rob Stachlewitz se une como CEO, mientras que el actual CEO Pat Bennett transita al puesto de Director de Negocios y Presidente de Asuntos Científicos. Honggang Bi ha sido nombrado Presidente de la Junta. La compañía, respaldada por Ampersand Capital Partners y KKR, se ha expandido globalmente a través de adquisiciones, incluyendo Alliance Pharma, Drug Development Solutions y Denali MedPharm, estableciendo operaciones en cuatro continentes. La reorganización tiene como objetivo apoyar las crecientes necesidades de los clientes y mejorar las operaciones globales.
Resolian은 생물 분석 및 분석 과학 분야의 글로벌 파트너로 주요 리더십 변화를 발표했습니다. Rob Stachlewitz가 CEO로 합류하고, 현재 CEO인 Pat Bennett는 최고 비즈니스 책임자 및 과학 업무의 회장으로 전환됩니다. Honggang Bi는 이사회 의장으로 임명되었습니다. Ampersand Capital Partners와 KKR의 지원을 받는 이 회사는 Alliance Pharma, Drug Development Solutions 및 Denali MedPharm을 포함한 인수를 통해 전 세계적으로 확장하였으며, 4개 대륙에 걸쳐 운영을 구축했습니다. 이번 조직 개편은 증가하는 고객의 요구를 지원하고 글로벌 운영을 강화하는 것을 목표로 하고 있습니다.
Resolian, un partenaire mondial dans le domaine des sciences bioanalytiques et analytiques, a annoncé des changements clés dans la direction. Rob Stachlewitz rejoint l'entreprise en tant que PDG, tandis que l'actuel PDG Pat Bennett passe à la fonction de directeur des affaires et président des affaires scientifiques. Honggang Bi a été nommé président du conseil d'administration. L'entreprise, soutenue par Ampersand Capital Partners et KKR, s'est développée à l'échelle mondiale grâce à des acquisitions telles qu'Alliance Pharma, Drug Development Solutions et Denali MedPharm, établissant des opérations sur quatre continents. La réorganisation vise à répondre aux besoins croissants des clients et à améliorer les opérations mondiales.
Resolian, ein globaler Partner im Bereich bioanalytischer und analytischer Wissenschaften, hat wichtige Führungswechsel angekündigt. Rob Stachlewitz tritt als CEO bei, während der aktuelle CEO Pat Bennett zum Chief Business Officer und Präsidenten der wissenschaftlichen Angelegenheiten wechselt. Honggang Bi wurde zum Vorsitzenden des Boards ernannt. Das Unternehmen, das von Ampersand Capital Partners und KKR unterstützt wird, hat sich durch Akquisitionen wie Alliance Pharma, Drug Development Solutions und Denali MedPharm global ausgeweitet und seine Aktivitäten auf vier Kontinenten etabliert. Die Umstrukturierung zielt darauf ab, den wachsenden Kundenbedarf zu unterstützen und die globalen Operationen zu verbessern.
- Global expansion through strategic acquisitions across four continents
- Strong financial backing from major investors (Ampersand Capital Partners and KKR)
- Experienced leadership team with combined decades of industry expertise
- None.
New leadership and reorganization will foster the next chapter of growth and enhance business operations to best support evolving client and CRO partner needs on a global scale.
Backed by
"It's an honor to be appointed Chairman of Resolian. I am excited to work alongside Rob, Pat, the Ampersand and KKR teams, and our nearly 500 dedicated global employees. Resolian is an innovative, global, bioanalytical and analytical CRO. I am confident we have the leadership, vision and dedicated quality-driven team to execute our clients' therapeutic programs," said Honggang Bi. Newly-appointed Chairman Honggang Bi posesses a more than 30 year illustrious career with Pfizer, Covance and Labcorp, leading their drug development operations across multiple geographies.
Incoming CEO Rob Stachlewitz joins Resolian with an impressive track record, having most recently served as Corporate Vice President and General Manager at Charles River, where he oversaw their largest site. Rob brings 15 years of pharmaceutical R&D experience, having held key roles at Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble. As CEO, Rob will guide Resolian through its next phase of strategic growth, enhancing its operational capabilities and global presence.
"With Rob's extensive background shepherding life science businesses and teams on a global scale, we are confident that he will lead Resolian to new heights as we continue to expand our bioanalytical operations," added Honggang Bi. Rob holds a PhD from the University of
Pat Bennett, who has led Resolian for nearly three years, has been instrumental in strategically positioning and steering the organization through a dynamic and transformative period, harmonizing operations, and driving global expansion. As Chief Business Officer and President of Scientific Affairs, Pat will focus on growing new service capabilities and enhancing customer relationships, leveraging his 30+ years of experience in bioanalytical sciences and business development. Pat will also oversee several critical functions to foster client collaboration and synergies across the Resolian team.
"We are incredibly grateful for Pat's leadership during a pivotal time in Resolian's history," said Dave Patteson, Partner, Ampersand Capital Partners. "As he transitions into his new role, Pat will continue to make critical contributions to Resolian's future growth and innovation. The combined leadership of Honggang, Rob and Pat is unrivaled in the bioanalytical CRO industry. The Resolian team will provide industry leading bioanalytical services to clients for their drug development projects across all major geographies."
About Resolian
Resolian (formerly Alliance Pharma Inc., Drug Development Solutions Ltd. and Chongqing Denali Medpharma, Ltd.) is a leading global research laboratory that provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. Nearly 500 experts across the
About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/resolian-appoints-rob-stachlewitz-as-ceo-honggang-bi-as-chairman-of-the-board-and-pat-bennett-as-chief-business-officer-and-president-of-scientific-affairs-302289255.html
SOURCE Resolian
FAQ
Who is the new CEO of Resolian as of October 2024?
What major acquisitions has Resolian made since 2022?
What is KKR's role in Resolian's business structure?
What is Pat Bennett's new role at Resolian?
